pcDNA3.2 TDP-43 NLS1 YFP Citations (2)

Originally described in: Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS.
Elden AC, Kim HJ, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, Armakola M, Geser F, Greene R, Lu MM, Padmanabhan A, Clay-Falcone D, McCluskey L, Elman L, Juhr D, Gruber PJ, Rub U, Auburger G, Trojanowski JQ, Lee VM, Van Deerlin VM, Bonini NM, Gitler AD Nature. 2010 Aug 26;466(7310):1069-75. doi: 10.1038/nature09320. PubMed Journal

---

Articles Citing pcDNA3.2 TDP-43 NLS1 YFP

Articles
RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43. Mann JR, Gleixner AM, Mauna JC, Gomes E, DeChellis-Marks MR, Needham PG, Copley KE, Hurtle B, Portz B, Pyles NJ, Guo L, Calder CB, Wills ZP, Pandey UB, Kofler JK, Brodsky JL, Thathiah A, Shorter J, Donnelly CJ. Neuron. 2019 Feb 27. pii: S0896-6273(19)30075-3. doi: 10.1016/j.neuron.2019.01.048. PubMed
Astrocytic TDP-43 dysregulation impairs memory by modulating antiviral pathways and interferon-inducible chemokines. Licht-Murava A, Meadows SM, Palaguachi F, Song SC, Jackvony S, Bram Y, Zhou C, Schwartz RE, Froemke RC, Orr AL, Orr AG. Sci Adv. 2023 Apr 21;9(16):eade1282. doi: 10.1126/sciadv.ade1282. Epub 2023 Apr 19. PubMed

If you have published an article using this material, please email us at to have your article added to this page.